Cytokinetics, Inc.

Bristol Myers Squibb anticipates expanding the pool of patients eligible for Camzyos (mavacamten) in the treatment of obstructive hypertrophic cardiomyopathy (oHCM) with the US Food and Drug Administr

Bristol Myers Squibb’s announcement that Camzyos (mavacamten) failed in a Phase III trial in class II-III non-obstructive hypertrophic cardiomyopathy (nHCM) was light on details. But its broader impli

Edgewise Therapeutics reported new data from an ongoing Phase II trial of its cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy (HCM) on 2 April that it contends could improve upon t

Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed t